CareDx achieved a 25% year-over-year revenue increase in Q4 2025, reaching $108.4 million. While the company reported a GAAP net loss of $4.1 million, it maintained positive adjusted EBITDA and strong cash flow from operations, ending the year with a solid cash position of approximately $200 million.
Total revenue for Q4 2025 grew 25% year-over-year to $108.4 million.
Testing services volume increased by 17% year-over-year to approximately 53,000 tests.
Patient and digital solutions revenue saw significant growth of 47% compared to the prior year.
The company ended 2025 with $201 million in cash, equivalents, and marketable securities after $88 million in share repurchases.
For the full year 2026, CareDx expects revenue to be in the range of $420 million to $444 million and adjusted EBITDA between $30 million and $45 million.
Visualization of income flow from segment revenue to net income
Analyze how earnings announcements historically affect stock price performance